Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!
Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer
Our goal is to expand the therapeutic potential of protein-drug conjugates by increasing design flexibility while overcoming constraints of toxicity, efficacy, and indication. Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.